Peptides for in development, ranked by human evidence
Peptide drugs approved since 2025, filed, or still in trials — the ones coming next, ranked by how far their human evidence has progressed. They are ranked by an evidence score that weighs the grade of the evidence, the human trials counted in PubMed, and regulatory status — shown in the columns so any rank can be checked. A high score means a peptide is well studied and often approved for something, not that it is right, safe or legal for this goal. Nothing here is medical advice, and Grey Peptides sells nothing and links to no vendor. See all goals or the plainer browse by goal map.
50 peptides · sorted by evidence score (click a column to re-sort)
| Peptide | Grade | Human studies | RCTs | Max trial phase | Regulatory | Dose | Score |
|---|---|---|---|---|---|---|---|
| Apitegromab | High | 12 | 4 | Phase 3 | FDA approved | intravenous infusion → | 100 |
| Insulin efsitora alfa | High | 94 | 29 | Phase 3 | FDA approved | — | 90 |
| Efpeglenatide | High | 38 | 12 | Phase 3 | In trials | subcutaneous → | 90 |
| Apraglutide | High | 25 | 2 | Phase 3 | In development | subcutaneous → | 90 |
| Taspoglutide | High | 55 | 11 | Phase 3 | Discontinued | subcutaneous → | 85 |
| CagriSema | High | 40 | 10 | Phase 3 | In development | subcutaneous → | 80 |
| Bimagrumab | Medium | 88 | 15 | Phase 3 | In trials | — | 70 |
| Efruxifermin | Medium | 27 | 6 | Phase 3 | In trials | subcutaneous → | 70 |
| Pegozafermin | Medium | 25 | 6 | Phase 3 | In trials | subcutaneous → | 70 |
| Solnatide | Medium | 21 | 6 | Phase 2 | In trials | inhaled → | 70 |
| Garetosmab | Medium | 15 | 6 | Phase 3 | FDA approved | — | 70 |
| Bofanglutide | Medium | 7 | 6 | Phase 3 | In trials | subcutaneous → | 70 |
| Canvuparatide | Medium | 3 | 2 | Phase 3 | In trials | subcutaneous → | 70 |
| ECC5004 | Medium | 2 | 2 | Phase 3 | In trials | oral → | 70 |
| VK2735 | Medium | 1 | 1 | Phase 3 | In trials | subcutaneous → | 70 |
| Danuglipron | Medium | 37 | 5 | Phase 2 | Discontinued | — | 65 |
| Pegbelfermin | Medium | 17 | 5 | Phase 2 | Discontinued | subcutaneous → | 65 |
| Relamorelin | Medium | 40 | 10 | Phase 3 | In trials | subcutaneous → | 60 |
| Petrelintide | Medium | 32 | 7 | Phase 3 | In trials | subcutaneous → | 60 |
| Glepaglutide | Medium | 26 | 8 | Phase 3 | In trials | subcutaneous → | 60 |
| Amycretin | Medium | 15 | 4 | Phase 1 | In trials | subcutaneous or oral → | 60 |
| Maridebart cafraglutide | Medium | 15 | 2 | Phase 3 | In trials | subcutaneous → | 60 |
| Pemvidutide | Medium | 9 | 2 | Phase 3 | In trials | subcutaneous → | 60 |
| Eneboparatide | Medium | 5 | 0 | Phase 3 | In trials | subcutaneous → | 60 |
| Enicepatide | Medium | 2 | 1 | Phase 3 | In trials | subcutaneous → | 60 |
| Eftansomatropin alfa | Medium | 1 | 1 | — | Approved abroad | — | 60 |
| UBT251 | Medium | 0 | 0 | Phase 3 | In trials | subcutaneous → | 60 |
| Cotadutide | Medium | 51 | 14 | Phase 2 | Discontinued | subcutaneous → | 55 |
| Seglitide | Medium | 25 | 0 | — | Discontinued | intravenous → | 55 |
| LSALT peptide | Low | 4 | 1 | Phase 3 | In trials | intravenous infusion → | 50 |
| Taldefgrobep alfa | Medium | 4 | 0 | Phase 3 | In trials | — | 50 |
| Efmedaglutide alfa | Low | 3 | 2 | — | In trials | subcutaneous → | 50 |
| HRS-9531 | Medium | 0 | 0 | Phase 3 | In trials | subcutaneous → | 45 |
| Olatorepatide | Medium | 0 | 0 | Phase 3 | In trials | — | 45 |
| HM15136 | Low | 3 | 2 | Phase 2 | In trials | — | 40 |
| KN056 | Low | 1 | 1 | Phase 1 | In trials | subcutaneous → | 40 |
| Zelpultide alfa | Low | 0 | 0 | Phase 3 | In trials | intratracheal → | 40 |
| Tabimorelin | Low | 7 | 4 | — | Discontinued | oral → | 35 |
| Veldoreotide | Low | 13 | 0 | Phase 1 | Approved abroad | — | 30 |
| Efocipegtrutide | Low | 4 | 0 | Phase 2 | In trials | — | 30 |
| Trevogrumab | Low | 4 | 0 | Phase 2 | In trials | — | 30 |
| AZD6234 | Low | 2 | 0 | Phase 3 | In trials | — | 30 |
| Obinepitide | Low | 1 | 0 | — | In trials | — | 30 |
| Sonefpeglutide | Low | 1 | 0 | Phase 2 | In trials | — | 30 |
| Utreglutide | Low | 1 | 0 | — | In trials | — | 30 |
| GMA106 | Low | 0 | 0 | Phase 1 | In trials | — | 25 |
| HM15275 | Low | 0 | 0 | Phase 2 | In trials | — | 25 |
| PB-718 | Low | 0 | 0 | Phase 2 | In trials | — | 25 |
| Colulintide | Low | 0 | 0 | — | Discontinued | — | 20 |
| Elsiglutide | Low | 0 | 0 | Phase 2 | Discontinued | — | 20 |
Other goals: Weight loss and metabolism · Healing, injury and recovery · Skin and hair · Focus, mood and the brain · Growth hormone and body composition · Heart and circulation · Sexual and reproductive health · Longevity and cell health · Immune defence and infection · Diagnostic and research tools
How the evidence score works
Evidence score (0-100), a transparent ranking aid, not a verdict. grade: high=60, medium=40, low=20, ungraded=0. Human trial: an on-site read-and-cited randomized or clinical trial = +15, else any PubMed human-indexed record = +5, else 0. RCT literature: PubMed lists >=1 randomized controlled trial = +10. Regulatory: FDA-approved = +15, in trials / approved-abroad / in development = +5, else 0. Every component is stored on each record so the number can be re-derived; volume and grade are shown together so neither misleads.
“Human studies” and “RCTs” are PubMed record counts for the peptide (read 2026-11-07 from the counts behind the Evidence Explorer); a count is how much research exists and of what kind, never proof a peptide works. “Grade” is our editorial reading of the evidence — see how we grade evidence. The “Dose” column links to the entry for each peptide that carries a dose from a regulator’s label or a published human study — where the amount is shown with its source; the amount is never reprinted here without that source, and many research peptides have no human dose, shown as —. Of 660 peptides, 607 have at least one human-indexed PubMed record, 324 cite a human trial on their page, 124 are FDA-approved, and 271 carry a sourced dose.